SCHEMBL4074874

SCHEMBL4074874

CC(C)[Si](F)(c1cccc(CCOC2CCCCO2)c1)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
DHFR P00374 1/20 0.35
P2RX3 P56373 6/20 0.34
CHEK1 O14757 1/20 0.34
KCNA5 P22460 1/20 0.33
SCN5A Q14524 1/20 0.33
GRM5 P41594 1/20 0.33
TGFBR1 P36897 1/20 0.32
TGFBR2 P37173 1/20 0.32
PTAFR P25105 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074856 0.93 KDM4C (0.43) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL13933489 0.86 KDM4C (0.46) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL4078449 0.86 KDM4C (0.46) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL14065688 0.79 KDM4C (0.51) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL4072226 0.79 MEN1 (0.42) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL4074956 0.78 KDM4C (0.46) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL4651147 0.78 KDM4C (0.47) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL4082834 0.77 KDM4C (0.52) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL4070469 0.77 KDM4C (0.51) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL10686057 0.77 KDM4C (0.51) KDM4CL3MBTL1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074135-A2 SILICON DERIVATIVES FOR PET IMAGING Bayer Schering Pharma AG (DE) 2009-07-01 EP disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
EP-1970064-A1 Silicon-derivatives for pet-imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-17 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035215-A1 RADIOFLUORINATION AFF2, AFF1, NUTF2 KDM4C 2028/4885L3MBTL1 299/4885NPC1 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.